Molecular targets on mast cells and basophils for novel therapies

Journal of Allergy and Clinical Immunology

Volumn 134, Issue 3, 2014, Pages 530-544

  Harvima, Ilkka T ^a   Levi Schaffer, Francesca ^b   Draber, Petr ^c   Friedman, Sheli ^b   Polakovicova, Iva ^c   Gibbs, Bernhard F ^d   Blank, Ulrich ^e,f   Nilsson, Gunnar ^g   Maurer, Marcus ^h  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g KAROLINSKA INSTITUTE   (Sweden)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

basophil; drug; Mast cell; mediator; receptor; signaling protein; survival protein; therapy

Indexed keywords

BRUTON TYROSINE KINASE; CANNABINOID RECEPTOR; CD48 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; DASATINIB; FC RECEPTOR; FC RECEPTOR IIB; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G; LAROPIPRANT; MASITINIB; MONTELUKAST; NAFAMSTAT MESILATE; NEUTRALIZING ANTIBODY; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PRANLUKAST; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PROTEINASE; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SPHINGOSINE 1 PHOSPHATE; THYMIC STROMAL LYMPHOPOIETIN; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON; ANTIALLERGIC AGENT; ION CHANNEL;

ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; APOPTOSIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; B CELL LYMPHOMA; BASOPHIL; CONJUNCTIVITIS; HUMAN; INTRACELLULAR SIGNALING; MAST CELL; MEDIATOR; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SURVIVAL; URTICARIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DEGRANULATION; DRUG EFFECTS; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; ANTI-ALLERGIC AGENTS; APOPTOSIS; BASOPHILS; CELL ADHESION MOLECULES; CELL DEGRANULATION; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; ION CHANNELS; MAST CELLS; MOLECULAR TARGETED THERAPY; RECEPTORS, CANNABINOID; RECEPTORS, IGE;

EID: 84906945203     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.03.007     Document Type: Review

References (239)

1. I.T. Harvima, and G. Nilsson Mast cells as regulators of skin inflammation and immunity Acta Derm Venereol 91 2011 644 650
2. F.H. Falcone, E.F. Knol, and B.F. Gibbs The role of basophils in the pathogenesis of allergic disease Clin Exp Allergy 41 2011 939 947
3. L. Karra, B. Berent-Maoz, M. Ben-Zimra, and F. Levi-Schaffer Are we ready to downregulate mast cells? Curr Opin Immunol 21 2009 708 714
4. H. Migalovich-Sheikhet, S. Friedman, D. Mankuta, and F. Levi-Schaffer Novel identified receptors on mast cells Front Immunol 3 2012 238
5. Y. Bounab, A. Getahun, J.C. Cambier, and M. Daeron Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells Curr Opin Immunol 25 2013 313 320
6. N.A. Pullen, Y.T. Falanga, J.K. Morales, and J.J. Ryan The Fyn-STAT5 pathway: a new frontier in IgE- and IgG-mediated mast cell signaling Front Immunol 3 2012 117
7. S. Jogie-Brahim, H.K. Min, Y. Fukuoka, H.Z. Xia, and L.B. Schwartz Expression of α-tryptase and β-tryptase by human basophils J Allergy Clin Immunol 113 2004 1086 1092
8. G.H. Caughey Mast cell tryptases and chymases in inflammation and host defense Immunol Rev 217 2007 141 154
9. K.D. Rice, R.D. Tanaka, B.A. Katz, R.P. Numerof, and W.R. Moore Inhibitors of tryptase for the treatment of mast cell-mediated diseases Curr Pharm Des 4 1998 381 396
10. A. He, and G.P. Shi Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases Curr Pharm Des 19 2013 1114 1125
11. M.T. Krishna, A. Chauhan, L. Little, K. Sampson, R. Hawksworth, and T. Mant et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma J Allergy Clin Immunol 107 2001 1039 1045
12. W.J. Tremaine, A. Brzezinski, J.A. Katz, D.C. Wolf, T.J. Fleming, and J. Mordenti et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study Aliment Pharmacol Ther 16 2002 407 413
13. S. Mori, Y. Itoh, R. Shinohata, T. Sendo, R. Oishi, and M. Nishibori Nafamostat mesilate is an extremely potent inhibitor of human tryptase J Pharmacol Sci 92 2003 420 423
14. J. Hallgren, S. Estrada, U. Karlson, K. Alving, and G. Pejler Heparin antagonists are potent inhibitors of mast cell tryptase Biochemistry 40 2001 7342 7349
15. N.M. Schechter, J.L. Sprows, O.L. Schoenberger, G.S. Lazarus, B.S. Cooperman, and H. Rubin Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors J Biol Chem 264 1989 21308 21315
16. M. Huttunen, and I.T. Harvima Mast cell tryptase and chymase in chronic leg ulcers: chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors Br J Dermatol 152 2005 1149 1160
17. P. D'Orléans-Juste, M. Houde, G.A. Rae, G. Bkaily, E. Carrier, and E. Simard Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies Vascul Pharmacol 49 2008 51 62
18. E. Yahiro, S. Miura, S. Imaizumi, Y. Uehara, and K. Saku Chymase inhibitors Curr Pharm Des 19 2013 3065 3071
19. B.E. Maryanoff, L. de Garavilla, M.N. Greco, B.J. Haertlein, G.I. Wells, and P. Andrade-Gordon et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation Am J Respir Crit Care Med 181 2010 247 253
20. N. Di Girolamo, and D. Wakefield In vitro and in vivo expression of interstitial collagenase/MMP-1 by human mast cells Dev Immunol 7 2000 131 142
21. N. Di Girolamo, I. Indoh, N. Jackson, D. Wakefield, H.P. McNeil, and W. Yan et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration J Immunol 177 2006 2638 2650
22. Z.-G. Shi, J.-P. Li, L.-L. Shi, and X. Li An updated patent therapeutic agents targeting MMPs Recent Pat Anticancer Drug Discov 7 2012 74 101
23. 84 bond by mast cell chymase J Biol Chem 269 1994 18134 18140
24. 92 bonds of the catalytic domain J Biol Chem 272 1997 25628 25635
25. B.L. Gruber, M.J. Marchese, K. Suzuki, L.B. Schwartz, Y. Okada, and H. Nagase et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation J Clin Invest 84 1989 1657 1662
26. B.F. Gibbs, and F. Levi-Schaffer H4 receptors in mast cells and basophils: a new therapeutic target for allergy? Front Biosci 17 2012 430 437
27. Y. Ohsawa, and N. Hirasawa The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice Allergy 67 2012 1014 1022
28. F. Levi-Schaffer, and R. Eliashar Mast cell stabilizing properties of antihistamines J Invest Dermatol 129 2009 2549 2551
29. K. Weller, and M. Maurer Desloratadine inhibits human skin mast cell activation and histamine release J Invest Dermatol 129 2009 2723 2726
30. K. Krause, A. Spohr, T. Zuberbier, M.K. Church, and M. Maurer Up-dosing with bilastine results in improved effectiveness in cold contact urticaria Allergy 68 2013 921 928
31. E. Masini, P. Blandina, S. Brunelleschi, and P.F. Mannaioni Evidence for H2-receptor-mediated inhibition of histamine release from isolated rat mast cells Agents Actions 12 1982 85 88
32. W. Kazimierczak, K. Szczepaniak, and K. Bańkowska A modulation of the anaphylactic basophil histamine release by selective H2 histamine agonists Agents Actions 11 1981 96 98
33. R. Summers, R. Sigler, J.H. Shelhamer, and M. Kaliner Effects of infused histamine on asthmatic and normal subjects: comparison of skin test responses J Allergy Clin Immunol 67 1981 456 464
34. S.P. Peters, A. Kagey-Sobotka, D.W. MacGlashan Jr., M.I. Siegel, and L.M. Lichtenstein The modulation of human basophil histamine release by products of the 5-lipoxygenase pathway J Immunol 129 1982 797 803
35. N. Novak, N. Mete, C. Bussmann, L. Maintz, T. Bieber, and M. Akdis et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 J Allergy Clin Immunol 130 2012 1153 1158.e2
36. J. Kleine-Tebbe, J. Schramm, M. Bolz, R. Lipp, W. Schunack, and G. Kunkel Influence of histamine H3-antagonists on human leukocytes Agents Actions 30 1990 137 139
37. A. Tedeschi, M. Lorini, M. Arquati, and A. Miadonna Regulation of histamine release from human basophil leucocytes: role of H1, H2 and H3 receptors Allergy 46 1991 626 631
38. U. Lippert, M. Artuc, A. Grutzkau, M. Babina, S. Guhl, and I. Haase et al. Human skin mast cells express H2 and H4, but not H3 receptors J Invest Dermatol 123 2004 116 123
39. C.L. Hofstra, P.J. Desai, R.L. Thurmond, and W.P. Fung-Leung Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells J Pharmacol Exp Ther 305 2003 1212 1221
40. R.L. Thurmond, P.J. Desai, P.J. Dunford, W.P. Fung-Leung, C.L. Hofstra, and W. Jiang et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties J Pharmacol Exp Ther 309 2004 404 413
41. Y. Shiraishi, Y. Jia, J. Domenico, A. Joetham, H. Karasuyama, and K. Takeda et al. Sequential engagement of FcεRI on mast cells and basophil histamine H(4) receptor and FcεRI in allergic rhinitis J Immunol 190 2013 539 548
42. R. Gutzmer, M. Gschwandtner, K. Rossbach, S. Mommert, T. Werfel, and M. Kietzmann et al. Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus Front Biosci (Schol Ed) 3 2011 985 994
43. 4 receptor antagonists ineffective against itch and skin inflammation in atopic dermatitis mouse model J Invest Dermatol 134 2014 546 548
44. C. Salcedo, C. Pontes, and M. Merlos Is the H4 receptor a new drug target for allergies and asthma? Front Biosci (Elite Ed) 5 2013 178 187
45. P. Montuschi, and M.L. Peters-Golden Leukotriene modifiers for asthma treatment Clin Exp Allergy 40 2010 1732 1741
46. T.M. Laidlaw, and J.A. Boyce Cysteinyl leukotriene receptors, old and new: implications for asthma Clin Exp Allergy 42 2012 1313 1320
47. A.H. Kubavat, N. Khippal, S. Tak, P. Rijhwani, S. Bhargava, and T. Patel et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma Am J Ther 20 2013 154 162
48. S.E. Kent, M. Boyce, Z. Diamant, D. Singh, B.J. O'Connor, and P.S. Saggu et al. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma Clin Exp Allergy 43 2013 177 186
49. M. Gulliksson, Å. Brunnström, M. Johannesson, L. Backman, G. Nilsson, and I. Harvima et al. Expression of 15-lipoxygenase type-1 in human mast cells Biochim Biophys Acta 1771 2007 1156 1165
50. S.G. Jeon, H.-G. Moon, Y.-S. Kim, J.-P. Choi, T.-S. Shin, and S.-W. Hong et al. 15-Lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA Clin Exp Allergy 39 2009 908 917
51. G. Rai, V. Kenyon, A. Jadhav, L. Schultz, M. Armstrong, and J.B. Jameson et al. Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1 J Med Chem 53 2010 7392 7404
52. S.-E. Dahlén, and M. Kumlin Monitoring mast cell activation by prostaglandin D2 in vivo Thorax 59 2004 453 455
53. R. Schuligoi, E. Sturm, P. Luschnig, V. Konya, S. Philipose, and M. Sedej et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases Pharmacology 85 2010 372 382
54. M. Joo, and R.T. Sadikot PGD synthase and PGD2 in immune response Mediators Inflamm 2012 2012 503128
55. T. Ugajin, T. Satoh, T. Kanamori, K. Aritake, Y. Urade, and H. Yokozeki FcεRI, but not FcγR, signals induce prostaglandin D2 and E2 production from basophils Am J Pathol 179 2011 775 782
56. G. Davì, F. Santilli, and N. Vazzana Thromboxane receptors antagonists and/or synthase inhibitors Handb Exp Pharmacol 210 2012 261 286
57. F. Horak, R. Zieglmayer, P. Lemell, L.P. Collins, M.G. Hunter, and J. Steiner et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomized, placebo-controlled, double-blind trial Allergy 67 2012 1572 1579
58. N. Barnes, I. Pavord, A. Chuchalin, J. Bell, M. Hunter, and T. Lewis et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin Exp Allergy 42 2011 38 48
59. A. Straumann, S. Hoesli, Bussmann Ch, M. Stuck, M. Perkins, and L.P. Collins et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis Allergy 68 2013 375 385
60. 2 receptor antagonist AMG 853 in asthmatic patients J Allergy Clin Immunol 131 2013 339 345
61. G. Philip, J. van Adelsberg, T. Loeys, N. Liu, P. Wong, and E. Lai et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis J Allergy Clin Immunol 124 2009 942 948
62. T. Nabe, Y. Kuriyama, N. Mizutani, S. Shibayama, A. Hiromoto, and M. Fujii et al. Inhibition of hematopoietic prostaglandin D synthase improves allergic nasal blockage in guinea pigs Prostaglandins Other Lipid Med 95 2011 27 34
63. D. Kajiwara, H. Aoyagi, K. Shigeno, M. Togawa, K. Tanaka, and N. Inagaki et al. Role of hematopoietic prostaglandin D synthase in biphasic nasal obstruction in guinea pig model of experimental allergic rhinitis Eur J Pharmacol 667 2011 389 395
64. E. Schneider, N. Thieblemont, M.L. De Moraes, and M. Dy Basophils: new players in the cytokine network Eur Cytokine Netw 21 2010 142 153
65. L. Ackermann, and I.T. Harvima Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis Arch Dermatol Res 290 1998 353 359
66. S. Falkencrone, L.K. Poulsen, C. Bindslev-Jensen, A. Woetmann, N. Odum, and B.C. Poulsen et al. IgE-mediated basophil tumour necrosis factor alpha induces matrix metalloproteinase-9 from monocytes Allergy 68 2013 614 620
67. M.M. Suttle, G. Nilsson, E. Snellman, and I.T. Harvima Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor Clin Exp Immunol 169 2012 311 319
68. J.S. Smolen, M.M. Schoels, N. Nishimoto, F.C. Breedveld, G.R. Burmester, and M. Dougados et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis 72 2013 482 492
69. A.M. Lin, C.J. Rubin, R. Khandpur, J.Y. Wang, M. Riblett, and S. Yalavarthi et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis J Immunol 187 2011 490 500
70. T.J. Kenna, and M.A. Brown The role of IL-17-secreting mast cells in inflammatory joint disease Nat Rev Rheumatol 9 2013 375 379
71. D.D. Patel, D.M. Lee, F. Kolbinger, and C. Antoni Effect of IL-17A blockade with secukinumab in autoimmune diseases Ann Rheum Dis 72 2013 ii116 ii123
72. M. Fischer, I.T. Harvima, R.F.S. Carvalho, C. Möller, A. Naukkarinen, and G. Enblad et al. Mast cell CD30 ligand is up-regulated in cutaneous inflammations and mediates degranulation-independent chemokine secretion J Clin Invest 116 2006 2748 2756
73. L. Skov, F.J. Beurskens, C.O.C. Zachariae, S. Reitamo, J. Teeling, and D. Satijn et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis J Immunol 181 2008 669 679
74. W. Tabrizi, B. Wang, H. Lu, S. Huang, G. Bell, and G. Schwab et al. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases Inflamm Allergy Drug Targets 9 2010 229 237
75. J.T. Schroeder Basophils: emerging roles in the pathogenesis of allergic disease Immunol Rev 242 2011 144 160
76. K.N. Messingham, T.A. Pietras, and J.A. Fairley Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies G Ital Dermatol Venereol 147 2012 251 257
77. T.K. Hart, M.N. Blackburn, M. Brigham-Burke, K. Dede, N. Al-Mahdi, and P. Zia-Amirhosseini et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma Clin Exp Immunol 130 2002 93 100
78. H. Karasuyama, K. Obata, T. Wada, Y. Tsujimura, and K. Mukai Newly appreciated roles for basophils in allergy and protective immunity Allergy 66 2011 1133 1141
79. E. Crivellato, L. Travan, and D. Ribatti Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation Int Arch Allergy Immunol 151 2009 89 97
80. V.V. Sumbayev, S.A. Nicholas, C.L. Streatfield, and B.F. Gibbs Involvement of hypoxia-inducible factor-1 HiF(1α) in IgE-mediated primary human basophil responses Eur J Immunol 39 2009 3511 3519
81. V.V. Sumbayev, I. Yasinska, A.E. Oniku, C.L. Streatfield, and B.F. Gibbs Involvement of hypoxia-inducible factor-1 in the inflammatory responses of human LAD2 mast cells and basophils PLoS One 7 2012 e34259
82. M. Gulliksson, R.F.S. Carvalho, E. Ullerås, and G. Nilsson Mast cell survival and mediator secretion in response to hypoxia PLoS One 5 2010 e12360
83. P. Lusková, and P. Dráber Modulation of the Fcε receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases Curr Pharm Des 10 2004 1727 1737
84. M. Riccaboni, I. Bianchi, and P. Petrillo Spleen tyrosine kinases: biology, therapeutic targets and drugs Drug Discov Today 15 2010 517 530
85. S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, and M. Baluom et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation J Pharmacol Exp Ther 319 2006 998 1008
86. M.E. Weinblatt, A. Kavanaugh, M.C. Genovese, D.A. Jones, T.K. Musser, and E.B. Grossbard et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial J Rheumatol 40 2013 369 378
87. D.L. Simmons Targeting kinases: a new approach to treating inflammatory rheumatic diseases Curr Opin Pharmacol 13 2013 426 434
88. B.J. Guyer, S.R. Shimamoto, A.L. Bradhurst, E.B. Grossbard, S.C. Dreskin, and H.S. Nelson Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis Allergy Asthma Proc 27 2006 208 213
89. E.S. Masuda, and J. Schmitz Syk inhibitors as treatment for allergic rhinitis Pulm Pharmacol Ther 21 2008 461 467
90. J.G. Foster, M.D. Blunt, E. Carter, and S.G. Ward Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies Pharmacol Rev 64 2012 1027 1054
91. M.D. Blunt, and S.G. Ward Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities Front Immunol 3 2012 226
92. T.M. Randis, K.D. Puri, H. Zhou, and T.G. Diacovo Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils Eur J Immunol 38 2008 1215 1224
93. K.S. Lee, H.K. Lee, J.S. Hayflick, Y.C. Lee, and K.D. Puri Inhibition of phosphoinositide 3-kinase δ attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model FASEB J 20 2006 455 465
94. L. So, and D.A. Fruman PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances Biochem J 442 2012 465 481
95. M.D. Blunt, and S.G. Ward Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities Front Immunol 3 2013 1 15
96. M.D. Blunt, and S.G. Ward Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia Curr Opin Pharmacol 12 2012 444 451
97. P. Norman Selective PI3Kδ inhibitors, a review of the patent literature Expert Opin Ther Pat 21 2011 1773 1790
98. J. Kalesnikoff, N. Baur, M. Leitges, M.R. Hughes, J.E. Damen, and M. Huber et al. SHIP negatively regulates IgE + antigen-induced IL-6 production in mast cells by inhibiting NF-κB activity J Immunol 168 2002 4737 4746
99. S.Y. Oh, T. Zheng, M.L. Bailey, D.L. Barber, J.T. Schroeder, and Y.K. Kim et al. Src homology 2 domain-containing inositol 5-phosphatase 1 deficiency leads to a spontaneous allergic inflammation in the murine lung J Allergy Clin Immunol 119 2007 123 131
100. D.J. Haddon, F. Antignano, M.R. Hughes, M.R. Blanchet, L. Zbytnuik, and G. Krystal et al. SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo J Immunol 183 2009 228 236
101. G.R. Stenton, L.F. Mackenzie, P. Tam, J.L. Cross, C. Harwig, and J. Raymond et al. Characterization of AQX-1125, a small molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo Br J Pharmacol 168 2013 1506 1518
102. G.R. Stenton, L.F. Mackenzie, P. Tam, J.L. Cross, C. Harwig, and J. Raymond et al. Characterization of AQX-1125, a small molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo Br J Pharmacol 168 2013 1519 1529
103. W. Ellmeier, A. Abramova, and A. Schebesta Tec family kinases: regulation of FcεRI-mediated mast-cell activation FEBS J 278 2011 1990 2000
104. L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, and B. Chang et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 107 2010 13075 13080
105. L. Soucek, J.J. Buggy, R. Kortlever, S. Adimoolam, H.A. Monclus, and M.T. Allende et al. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma Neoplasia 13 2011 1093 1100
106. D. MacGlashan Jr., L.A. Honigberg, A. Smith, J. Buggy, and J.T. Schroeder Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor Int Immunopharmacol 11 2011 475 479
107. B.Y. Chang, M.M. Huang, M. Francesco, J. Chen, J. Sokolove, and P. Magadala et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Arthritis Res Ther 13 2011 R115
108. E.K. Evans, R. Tester, S. Aslanian, R. Karp, M. Sheets, and M.T. Labenski et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans J Pharmacol Exp Ther 346 2013 219 228
109. O.J. D'Cruz, and F.M. Uckun Novel Bruton's tyrosine kinase inhibitors currently in development Onco Targets Ther 6 2013 161 176
110. C. Ustun, D.L. DeRemer, and C. Akin Tyrosine kinase inhibitors in the treatment of systemic mastocytosis Leuk Res 35 2011 1143 1152
111. S. Verstovsek, C. Akin, T. Manshouri, A. Quintas-Cardama, L. Huynh, and P. Manley et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit Leuk Res 30 2006 1365 1370
112. A. Vega-Ruiz, J.E. Cortes, M. Sever, T. Manshouri, A. Quintas-Cardama, and R. Luthra et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis Leuk Res 33 2009 1481 1484
113. K.K. Eklund, and H. Joensuu Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases Ann Med 35 2003 362 367
114. A. Juurikivi, C. Sandler, K.A. Lindstedt, P.T. Kovanen, T. Juutilainen, and M.J. Leskinen et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis Ann Rheum Dis 64 2005 1126 1131
115. A.G. Tristano Tyrosine kinases as targets in rheumatoid arthritis Int Immunopharmacol 9 2009 1 9
116. D.S. El-Agamy Anti-allergic effects of nilotinib on mast cell-mediated anaphylaxis like reactions Eur J Pharmacol 680 2012 115 121
117. M. Kneidinger, U. Schmidt, U. Rix, K.V. Gleixner, A. Vales, and C. Baumgartner et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils Blood 111 2008 3097 3107
118. C. Paul, B. Sans, F. Suarez, P. Casassus, S. Barete, and F. Lanternier et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study Am J Hematol 85 2010 921 925
119. M. Humbert, F. de Blay, G. Garcia, A. Prud'homme, C. Leroyer, and A. Magnan et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics Allergy 64 2009 1194 1201
120. J. Gotlib, D.J. DeAngelo, T.I. George, C.L. Corless, A. Linder, and C. Langford et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial Blood 116 2010 Abstract 316
121. P.S. Jolly, M. Bektas, A. Olivera, C. Gonzalez-Espinosa, R.L. Proia, and J. Rivera et al. Transactivation of sphingosine-1-phosphate receptors by FcεRI triggering is required for normal mast cell degranulation and chemotaxis J Exp Med 199 2004 959 970
122. A.J. Ammit, A.T. Hastie, L.C. Edsall, R.K. Hoffman, Y. Amrani, and V.P. Krymskaya et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma FASEB J 15 2001 1212 1214
123. C.A. Oskeritzian, S.E. Alvarez, N.C. Hait, M.M. Price, S. Milstien, and S. Spiegel Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions Blood 111 2008 4193 4200
124. J.J. Ryan, and S. Spiegel The role of sphingosine-1-phosphate and its receptors in asthma Drug News Perspect 21 2008 89 96
125. K. Hogenauer, A. Billich, C. Pally, M. Streiff, T. Wagner, and K. Welzenbach et al. Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues ChemMedChem 3 2008 1027 1029
126. K. Takabe, S.W. Paugh, S. Milstien, and S. Spiegel "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets Pharmacol Rev 60 2008 181 195
127. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, and G. Francis et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 2010 883 897
128. M. Vig, W.I. Dehaven, G.S. Bird, J.M. Billingsley, H. Wang, and P.E. Rao et al. Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release-activated calcium channels Nat Immunol 9 2008 89 96
129. Y. Baba, K. Nishida, Y. Fujii, T. Hirano, M. Hikida, and T. Kurosaki Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses Nat Immunol 9 2008 81 88
130. J.W. Putney Jr. Pharmacology of capacitative calcium entry Mol Interv 1 2001 84 94
131. 2+ channels J Biol Chem 283 2008 31348 31355
132. A.B. Parekh, and J.W. Putney Jr. Store-operated calcium channels Physiol Rev 85 2005 757 810
133. 2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis J Allergy Clin Immunol 124 2009 1014 1021
134. 2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity Mol Pharmacol 69 2006 1413 1420
135. L.P. He, T. Hewavitharana, J. Soboloff, M.A. Spassova, and D.L. Gill A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2 J Biol Chem 280 2005 10997 11006
136. T. Yoshino, J. Ishikawa, K. Ohga, T. Morokata, R. Takezawa, and H. Morio et al. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models Eur J Pharmacol 560 2007 225 233
137. H. Wulff, and N.A. Castle Therapeutic potential of KCa3.1 blockers: recent advances and promising trends Expert Rev Clin Pharmacol 3 2010 385 396
138. M. Ekoff, and G. Nilsson Mast cell apoptosis and survival Adv Exp Med Biol 716 2011 47 60
139. S.N. Willis, J.I. Fletcher, T. Kaufmann, M.F. van Delft, L. Chen, and P.E. Czabotar et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak Science 315 2007 856 859
140. Z. Xiang, C. Moller, and G. Nilsson IgE-receptor activation induces survival and Bfl-1 expression in human mast cells but not basophils Allergy 61 2006 1040 1046
141. M. Ekoff, K. Lyberg, M. Krajewska, M. Arvidsson, S. Rak, and J.C. Reed et al. Anti-apoptotic BFL-1 is the major effector in activation-induced human mast cell survival PLoS One 7 2012 e39117
142. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, and B.A. Belli et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
143. R.M. Mohammad, A.S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, and G. Wang et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 Clin Cancer Res 13 2007 2226 2235
144. C. Tse, A.R. Shoemaker, J. Adickes, M.G. Anderson, J. Chen, and S. Jin et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 2008 3421 3428
145. C.M. Rudin, C.L. Hann, E.B. Garon, O.M. Ribeiro de, P.D. Bonomi, and D.R. Camidge et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin Cancer Res 18 2012 3163 3169
146. M. Karlberg, M. Ekoff, D.C. Huang, P. Mustonen, I.T. Harvima, and G. Nilsson The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics J Immunol 185 2010 2555 2562
147. B. Peter, S. Cerny-Reiterer, E. Hadzijusufovic, K. Schuch, G. Stefanzl, and G. Eisenwort et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells J Leukoc Biol 95 2014 95 104
148. I. Bachelet, A. Munitz, A. Moretta, L. Moretta, and F. Levi-Schaffer The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells J Immunol 175 2005 7989 7995
149. A. Munitz, I. Bachelet, R. Eliashar, A. Moretta, L. Moretta, and F. Levi-Schaffer The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils Blood 107 2006 1996 2003
150. V. Sabato, M.M. Verweij, C.H. Bridts, F. Levi-Schaffer, B.F. Gibbs, and L.S. De Clerck et al. CD300a is expressed on human basophils and seems to inhibit IgE/FεRI-dependent anaphylactic degranulation Cytometry B Clin Cytom 82 2012 132 138
151. B.F. Gibbs, V. Sabato, C.H. Bridts, D.G. Ebo, M. Ben-Zimra, and F. Levi-Schaffer Expressions and inhibitory functions of CD300a receptors on purified human basophils Exp Dermatol 21 2012 884 886
152. I. Bachelet, A. Munitz, and F. Levi-Schaffer Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a J Allergy Clin Immunol 117 2006 1314 1320
153. W. Zhao, C.L. Kepley, P.A. Morel, L.M. Okumoto, Y. Fukuoka, and L.B. Schwartz Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells J Immunol 177 2006 694 701
154. L. Cassard, F. Jönsson, S. Arnaud, and M. Daëron Fcγ receptors inhibit mouse and human basophil activation J Immunol 189 2012 2995 3006
155. S. Cemerski, S.Y. Chu, G.L. Moore, U.S. Muchhal, J.R. Desjarlais, and D.E. Szymkowski Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb Immunol Lett 143 2012 34 43
156. C.T. Cady, M.S. Powell, R.J. Harbeck, P.C. Giclas, J.R. Murphy, and R.K. Katial et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB Immunol Lett 130 2010 57 65
157. H. Floyd, J. Ni, A.L. Cornish, Z. Zeng, D. Liu, and K.C. Carter et al. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily J Biol Chem 275 2000 861 866
158. K.K. Kikly, B.S. Bochner, S.D. Freeman, K.B. Tan, K.T. Gallagher, and K.J. D'alessio et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils J Allergy Clin Immunol 105 2000 1093 1100
159. T. Kiwamoto, N. Kawasaki, J.C. Paulson, and B.S. Bochner Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions Pharmacol Ther 135 2012 327 336
160. A. Pini, G. Mannaioni, D. Pellegrini-Giampietro, M.B. Passani, R. Mastroianni, and D. Bani et al. The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke Curr Drug Targets 13 2012 984 993
161. A. Munitz, I. Bachelet, and F. Levi-Schaffer Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a J Allergy Clin Immunol 118 2006 1082 1089
162. C. Nakahashi-Oda, S. Tahara-Hanaoka, M. Shoji, Y. Okoshi, T. Nakano-Yokomizo, and N. Ohkohchi et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor J Exp Med 209 2012 1493 1503
163. A.H. Nissim Ben Efraim, L. Karra, M. Ben-Zimra, and F. Levi-Schaffer The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils Allergy 68 2013 397 401
164. V.R. Simhadri, J.F. Andersen, E. Calvo, S.C. Choi, J.E. Coligan, and F. Borrego Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells Blood 119 2012 2799 2809
165. Y. Tsujimura, K. Obata, K. Mukai, H. Shindou, M. Yoshida, and H. Nishikado et al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis Immunity 28 2008 581 589
166. C.L. Kepley, J.C. Cambier, P.A. Morel, D. Lujan, E. Ortega, and B.S. Wilson et al. Negative regulation of FcεRI signaling by FcγRII costimulation in human blood basophils J Allergy Clin Immunol 106 2000 337 348
167. P. Bruhns, S. Frémont, and M. Daëron Regulation of allergy by Fc receptors Curr Opin Immunol 17 2005 662 669
168. Y. Okayama, A.S. Kirshenbaum, and D.D. Metcalfe Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: upregulation by IFN-γ J Immunol 164 2000 4332 4339
169. D. Zhu, C.L. Kepley, M. Zhang, K. Zhang, and A. Saxon A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation Nat Med 8 2002 518 521
170. D. Zhu, C.L. Kepley, K. Zhang, T. Terada, T. Yamada, and A. Saxon A chimeric human-cat fusion protein blocks cat-induced allergy Nat Med 11 2005 446 449
171. K. Zhang, C.L. Kepley, T. Terada, D. Zhu, H. Perez, and A. Saxon Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein J Allergy Clin Immunol 114 2004 321 327
172. L.H. Lin, P. Zheng, J.W. Yuen, J. Wang, J. Zhou, and C.Q. Kong et al. Prevention and treatment of allergic inflammation by an Fcγ-Der f2 fusion protein in a murine model of dust mite-induced asthma Immunol Res 52 2012 276 283
173. G. Foussias, G.M. Yousef, and E.P. Diamandis Molecular characterization of a Siglec8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the Siglec8 gene Biochem Biophys Res Commun 278 2000 775 781
174. H. Aizawa, J. Plitt, and B.S. Bochner Human eosinophils express two Siglec-8 splice variants J Allergy Clin Immunol 109 2002 176
175. S.A. Hudson, H. Herrmann, J. Du, P. Cox, el-B. Haddad, and B. Butler et al. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression J Clin Immunol 31 2011 1045 1053
176. H. Yokoi, A. Myers, K. Matsumoto, P.R. Crocker, H. Saito, and B.S. Bochner Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells Allergy 61 2006 769 776
177. H. Yokoi, O.H. Choi, W. Hubbard, H.S. Lee, B.J. Canning, and H.H. Lee et al. Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement J Allergy Clin Immunol 121 2008 499 505.e1
178. E. Nutku-Bilir, S.A. Hudson, and B.S. Bochner Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways Am J Respir Cell Mol Biol 38 2008 121 124
179. H.J. Na, S.A. Hudson, and B.S. Bochner IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils Cytokine 57 2012 169 174
180. S.A. Hudson, N.V. Bovin, R.L. Schnaar, P.R. Crocker, and B.S. Bochner Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6'-sulfated sialyl Lewis x J Pharmacol Exp Ther 330 2009 608 612
181. SSh Farid, A. Mirshafiey, and A. Razavi Siglec-8 and Siglec-F, the new therapeutic targets in asthma Immunopharmacol Immunotoxicol 34 2012 721 726
182. W.W. Stevens, T.S. Kim, L.M. Pujanauski, X. Hao, and T.J. Braciale Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry J Immunol Methods 327 2007 63 74
183. H. Tateno, H. Li, M.J. Schur, N. Bovin, P.R. Crocker, and W.W. Wakarchuk et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity Mol Cell Biol 27 2007 5699 5710
184. M. Zhang, T. Angata, J.Y. Cho, M. Miller, D.H. Broide, and A. Varki Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils Blood 109 2007 4280 4287
185. J.Y. Cho, D.J. Song, A. Pham, P. Rosenthal, M. Miller, and S. Dayan et al. Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13 Respir Res 11 2010 154
186. T. Kiwamoto, Y. Ishii, Y. Morishima, K. Yoh, N. Kikuchi, and N. Haraguchi et al. Blockade of cysteinyl leukotriene-1 receptors suppresses airway remodelling in mice overexpressing GATA-3 Clin Exp Allergy 41 2011 116 128
187. S. Merighi, C. Simioni, S. Gessi, K. Varani, and P.A. Borea Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors Biochem Pharmacol 79 2010 471 477
188. P. Pacher, and R. Mechoulam Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50 2011 193 211
189. C. Börner, V. Höllt, W. Sebald, and J. Kraus Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids J Leukoc Biol 81 2007 336 343
190. C. Börner, A. Bedini, V. Höllt, and J. Kraus Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes Mol Pharmacol 73 2008 1013 1019
191. K. Sugawara, N. Zákány, T. Hundt, V. Emelianov, D. Tsuruta, and C. Schäfer et al. Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ J Allergy Clin Immunol 132 2013 182 193
192. K. Sugawara, T. Bíró, D. Tsuruta, B.I. Tóth, A. Kromminga, and N. Zákány et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin J Allergy Clin Immunol 129 2012 726 738.e8
193. M.T. Samson, A. Small-Howard, L.M. Shimoda, M. Koblan-Huberson, A.J. Stokes, and H. Turner Differential roles of CB1 and CB2 cannabinoid receptors in mast cells J Immunol 170 2003 4953 4962
194. L. Aloe, A. Leon, and R. Levi-Montalcini A proposed autacoid mechanism controlling mastocyte behaviour Agents Actions 39 Spec No 1993 C145 C147
195. A.H. Lau, and S.S. Chow Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells Eur J Pharmacol 464 2003 229 235
196. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, and M. Horowitz et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor Proc Natl Acad Sci U S A 96 1999 14228 14233
197. L. Facci, R. Dal Toso, S. Romanello, A. Buriani, S.D. Skaper, and A. Leon Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide Proc Natl Acad Sci U S A 92 1995 3376 3380
198. M. Elishmereni, and F. Levi-Schaffer CD48: a co-stimulatory receptor of immunity Int J Biochem Cell Biol 43 2011 25 28
199. P.R. Giacomin, M.C. Siracusa, K.P. Walsh, R.K. Grencis, M. Kubo, and M.R. Comeau et al. Thymic stromal lymphopoietin-dependent basophils promote Th2 cytokine responses following intestinal helminth infection J Immunol 189 2012 4371 4378
200. R. Malaviya, Z. Gao, K. Thankavel, P.A. van der Merwe, and S.N. Abraham The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48 Proc Natl Acad Sci U S A 96 1999 8110 8115
201. R. Malaviya, and S.N. Abraham Mast cell modulation of immune responses to bacteria Immunol Rev 179 2001 16 24
202. T. Proft, and E.N. Baker Pili in gram-negative and gram-positive bacteria - structure, assembly and their role in disease Cell Mol Life Sci 66 2009 613 635
203. S. Muñoz, R. Hernández-Pando, S.N. Abraham, and J.A. Enciso Mast cell activation by Mycobacterium tuberculosis: mediator release and role of CD48 J Immunol 170 2003 5590 5596
204. C.M. Rocha-de-Souza, B. Berent-Maoz, D. Mankuta, A.E. Moses, and F. Levi-Schaffer Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules Infect Immun 76 2008 4489 4497
205. M. Elishmereni, H.T. Alenius, P. Bradding, S. Mizrahi, A. Shikotra, and Y. Minai-Fleminger et al. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro Allergy 66 2011 376 385
206. N. Zimmermann, N.E. King, J. Laporte, M. Yang, A. Mishra, and S.M. Pope et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis J Clin Invest 111 2003 1863 1874
207. A. Munitz, I. Bachelet, F.D. Finkelman, M.E. Rothenberg, and F. Levi-Schaffer CD48 is critically involved in allergic eosinophilic airway inflammation Am J Respir Crit Care Med 175 2007 911 918
208. Z. Allakhverdi, M.R. Comeau, H.K. Jessup, B.R. Yoon, A. Brewer, and S. Chartier et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells J Exp Med 204 2007 253 258
209. A. Astrakhan, M. Omori, T. Nguyen, S. Becker-Herman, M. Iseki, and T. Aye et al. Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development Nat Immunol 8 2007 522 531
210. Y.J. Liu, V. Soumelis, N. Watanabe, T. Ito, Y.H. Wang, and W. Malefyt Rde et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation Annu Rev Immunol 25 2007 193 219
211. M.C. Siracusa, S.A. Saenz, D.A. Hill, B.S. Kim, M.B. Headley, and T.A. Doering et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation Nature 477 2011 229 233
212. S.F. Ziegler, and D. Artis Sensing the outside world: TSLP regulates barrier immunity Nat Immunol 11 2010 289 293
213. L.S. Park, U. Martin, K. Garka, B. Gliniak, J.P. Di Santo, and W. Muller et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor J Exp Med 192 2000 659 670
214. M.R. Comeau, and S.F. Ziegler The influence of TSLP on the allergic response Mucosal Immunol 3 2010 138 147
215. A. Shikotra, D.F. Choy, C.M. Ohri, E. Doran, C. Butler, and B. Hargadon et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma J Allergy Clin Immunol 129 2012 104 111 e1-9
216. T.A. Le, T. Takai, A.T. Vu, H. Kinoshita, X. Chen, and S. Ikeda et al. Flagellin induces the expression of thymic stromal lymphopoietin in human keratinocytes via toll-like receptor 5 Int Arch Allergy Immunol 155 2011 31 37
217. D. Kaur, C. Doe, L. Woodman, W.Y. Wan, A. Sutcliffe, and F. Hollins et al. Mast cell-airway smooth muscle crosstalk: the role of thymic stromal lymphopoietin Chest 142 2012 76 85
218. F. Zhang, G. Huang, B. Hu, Y. Song, and Y. Shi A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells Clin Exp Immunol 164 2011 256 264
219. S.J. Galli, and M. Tsai IgE and mast cells in allergic disease Nat Med 18 2012 693 704
220. U. Blank, C. Ra, L. Miller, K. White, H. Metzger, and J.P. Kinet Complete structure and expression in transfected cells of high affinity IgE receptor Nature 337 1989 187 189
221. U. Blank, and J. Rivera The ins and outs of IgE-dependent mast-cell exocytosis Trends Immunol 25 2004 266 273
222. S.C. Garman, B.A. Wurzburg, S.S. Tarchevskaya, J.P. Kinet, and T.S. Jardetzky Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα Nature 406 2000 259 266
223. A. Kulczycki Jr., C. Isersky, and H. Metzger The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE J Exp Med 139 1974 600 616
224. H.L. Spiegelberg, K.M. Canning, M. Scheetz, G. Koppel, and J.M. Chiller Effect of myeloma IgE injections on passive and active cutaneous anaphylaxis in rats J Immunol 136 1986 131 135
225. L.D. Smith, R.J. Leatherbarrow, and A.C. Spivey Development of small molecules to target the IgE: FcεRI protein-protein interaction in allergies Future Med Chem 5 2013 1423 1435
226. J. Corren, T.B. Casale, B. Lanier, R. Buhl, S. Holgate, and P. Jimenez Safety and tolerability of omalizumab Clin Exp Allergy 39 2009 788 797
227. T.W. Chang, and Y.Y. Shiung Anti-IgE as a mast cell-stabilizing therapeutic agent J Allergy Clin Immunol 117 2006 1203 1212
228. M. Maurer, K. Rosén, H.J. Hsieh, S. Saini, C. Grattan, and A. Gimenéz-Arnau et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria N Engl J Med 368 2013 924 935
229. A. Rafi, L.T. Do, R. Katz, L.E. Sheinkopf, C.W. Simons, and W. Klaustermeyer Effects of omalizumab in patients with food allergy Allergy Asthma Proc 31 2010 76 83
230. L.E. Sheinkopf, A.W. Rafi, L.T. Do, R.M. Katz, and W.B. Klaustermeyer Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study Allergy Asthma Proc 29 2008 530 537
231. S.T. Holgate, R. Djukanović, T. Casale, and J. Bousquet Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy Clin Exp Allergy 35 2005 408 416
232. J.A. Lieberman, and M. Chehade Use of omalizumab in the treatment of food allergy and anaphylaxis Curr Allergy Asthma Rep 13 2013 78 84
233. A.M. Piliponsky, G.J. Gleich, A. Nagler, I. Bar, and F. Levi-Schaffer Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor Blood 101 2003 1898 1904
234. F. Hollins, D. Kaur, W. Yang, G. Cruse, R. Saunders, and A. Sutcliffe et al. Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6 J Immunol 181 2008 2772 2780
235. W. Yang, D. Kaur, Y. Okayama, A. Ito, A.J. Wardlaw, and C.E. Brightling et al. Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1 J Immunol 176 2006 1238 1243
236. E.P. Moiseeva, M.L. Leyland, and P. Bradding CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion Cell Mol Life Sci 69 2012 2751 2764
237. E.P. Moiseeva, K.M. Roach, M.L. Leyland, and P. Bradding CADM1 is a key receptor mediating human mast cell adhesion to human lung fibroblasts and airway smooth muscle cells PLoS One 8 2013 e61579
238. M. Hagiyama, T. Inoue, T. Furuno, T. Iino, S. Itami, and M. Nakanishi et al. Increased expression of cell adhesion molecule 1 by mast cells as a cause of enhanced nerve-mast cell interaction in a hapten-induced mouse model of atopic dermatitis Br J Dermatol 168 2013 771 778
239. I. Halova, L. Draberova, and P. Draber Mast cell chemotaxis - chemoattractants and signaling pathways Front Immunol 3 2012 119